Bio-Path开盘暴涨触发熔断，肥胖症实验性疗法取得积极结果

老虎资讯综合12-19

周四，药物开发商Bio-Path Holdings开盘暴涨触发熔断，现涨幅340.96%。消息面上，Bio-Path报告了一项临床前研究的积极结果，该研究测试其实验性疗法BP1001-A，以治疗2型糖尿病患者的肥胖症和相关代谢疾病。公司称，试验证实了BP1001-A在影响胰岛素信号传导方面的有效性。

公司已开始动物实验，以确认BP1001-A的疗效，并计划于2025年开始早期人体试验。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

阿Q郑赚
12-20
阿Q郑赚
不就是二甲双瓜吗
多多吃苹果
12-19
多多吃苹果
一大片蓝海……
- 军军2021:
  买的少赚了一点

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/1170079573?lang=zh_CN&edition=full","thumbnail":"https://static.tigerbbs.com/6ce1e2c9b06bd8104cffbddf43442c15","is_english":false,"pubTime":"2024-12-19 22:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1170079573","market":"us","top_or_hot":-1,"title":"Bio-Path开盘暴涨触发熔断，肥胖症实验性疗法取得积极结果","media":"老虎资讯综合","content":"<html><head></head><body><p>周四，药物开发商Bio-Path Holdings开盘暴涨触发熔断，现涨幅340.96%。消息面上，Bio-Path报告了一项临床前研究的积极结果，该研究测试其实验性疗法BP1001-A，以治疗2型糖尿病患者的肥胖症和相关代谢疾病。公司称，试验证实了BP1001-A在影响胰岛素信号传导方面的有效性。</p><p>公司已开始动物实验，以确认BP1001-A的疗效，并计划于2025年开始早期人体试验。</p><p></p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/1af69eaaf88a17b10941c28d63668c18\" tg-width=\"560\" tg-height=\"240\"/></p><p></p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bio-Path开盘暴涨触发熔断，肥胖症实验性疗法取得积极结果</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBio-Path开盘暴涨触发熔断，肥胖症实验性疗法取得积极结果\n</h2>\n\n<h4 class=\"meta\">\n\n2024-12-19 22:42 北京时间&nbsp;&nbsp;&nbsp;<strong>老虎资讯综合</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>周四，药物开发商Bio-Path Holdings开盘暴涨触发熔断，现涨幅340.96%。消息面上，Bio-Path报告了一项临床前研究的积极结果，该研究测试其实验性疗法BP1001-A，以治疗2型糖尿病患者的肥胖症和相关代谢疾病。公司称，试验证实了BP1001-A在影响胰岛素信号传导方面的有效性。公司已开始动物实验，以确认BP1001-A的疗效，并计划于2025年开始早期人体试验。</p>\n\n<a href=\"\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BPTH","symbol_name":"Bio-Path Holdings, Inc.","start_time":0,"source_url":"","article_id":"1170079573","we_media_id":"102","thumbnails":["https://static.tigerbbs.com/6ce1e2c9b06bd8104cffbddf43442c15"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1170079573","pubTimestamp":1734619328,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"老虎资讯综合","introduction":"为用户提供金融资讯、行情、数据，旨在帮助投资者理解世界，做投资决策。","home_visible":1,"id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"summary":"计划于2025年开始早期人体试验。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BPTH":"Bio-Path Holdings, Inc."},"translate_title":"Bio-Path's surge at opening triggers circuit breaker, experimental treatment for obesity achieves positive results","themeId":"c7d5dc247e4842683e20d8820e16915e","isJumpTheme":false,"ttsUrl":"https://static.tigerbbs.com/c32e4fd9f910a60b2325ef9166940755","symbols_score_info":{"BPTH":1.1},"content_text":"周四，药物开发商Bio-Path Holdings开盘暴涨触发熔断，现涨幅340.96%。消息面上，Bio-Path报告了一项临床前研究的积极结果，该研究测试其实验性疗法BP1001-A，以治疗2型糖尿病患者的肥胖症和相关代谢疾病。公司称，试验证实了BP1001-A在影响胰岛素信号传导方面的有效性。公司已开始动物实验，以确认BP1001-A的疗效，并计划于2025年开始早期人体试验。","kind":"news","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[{"id":383420821832216,"gmtCreate":1734649887479,"gmtModify":1734649889562,"author":{"id":"3583966900773329","authorId":"3583966900773329","name":"阿Q郑赚","avatar":"https://static.tigerbbs.com/5fb5ba8bd79b5d86de0725a6933c89b6","vip":1,"crmLevel":5,"crmLevelSwitch":0,"idStr":"3583966900773329","authorIdStr":"3583966900773329"},"htmlText":"不就是二甲双瓜吗","listText":"不就是二甲双瓜吗","text":"不就是二甲双瓜吗","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/383420821832216","repostId":1170079573,"repostType":2,"repost":{"id":"1170079573","kind":"news","weMediaInfo":{"introduction":"为用户提供金融资讯、行情、数据，旨在帮助投资者理解世界，做投资决策。","home_visible":1,"media_name":"老虎资讯综合","id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1734619328,"share":"https://www.laohu8.com/m/news/1170079573?lang=&edition=full","pubTime":"2024-12-19 22:42","market":"us","language":"zh","title":"Bio-Path开盘暴涨触发熔断，肥胖症实验性疗法取得积极结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1170079573","media":"老虎资讯综合","summary":"计划于2025年开始早期人体试验。","content":"<html><head></head><body><p>周四，药物开发商Bio-Path Holdings开盘暴涨触发熔断，现涨幅340.96%。消息面上，Bio-Path报告了一项临床前研究的积极结果，该研究测试其实验性疗法BP1001-A，以治疗2型糖尿病患者的肥胖症和相关代谢疾病。公司称，试验证实了BP1001-A在影响胰岛素信号传导方面的有效性。</p><p>公司已开始动物实验，以确认BP1001-A的疗效，并计划于2025年开始早期人体试验。</p><p></p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/1af69eaaf88a17b10941c28d63668c18\" tg-width=\"560\" tg-height=\"240\"/></p><p></p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bio-Path开盘暴涨触发熔断，肥胖症实验性疗法取得积极结果</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBio-Path开盘暴涨触发熔断，肥胖症实验性疗法取得积极结果\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/102\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">老虎资讯综合 </p>\n<p class=\"h-time\">2024-12-19 22:42</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>周四，药物开发商Bio-Path Holdings开盘暴涨触发熔断，现涨幅340.96%。消息面上，Bio-Path报告了一项临床前研究的积极结果，该研究测试其实验性疗法BP1001-A，以治疗2型糖尿病患者的肥胖症和相关代谢疾病。公司称，试验证实了BP1001-A在影响胰岛素信号传导方面的有效性。</p><p>公司已开始动物实验，以确认BP1001-A的疗效，并计划于2025年开始早期人体试验。</p><p></p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/1af69eaaf88a17b10941c28d63668c18\" tg-width=\"560\" tg-height=\"240\"/></p><p></p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/6ce1e2c9b06bd8104cffbddf43442c15","relate_stocks":{"BPTH":"Bio-Path Holdings, Inc."},"source_url":"","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1170079573","content_text":"周四，药物开发商Bio-Path Holdings开盘暴涨触发熔断，现涨幅340.96%。消息面上，Bio-Path报告了一项临床前研究的积极结果，该研究测试其实验性疗法BP1001-A，以治疗2型糖尿病患者的肥胖症和相关代谢疾病。公司称，试验证实了BP1001-A在影响胰岛素信号传导方面的有效性。公司已开始动物实验，以确认BP1001-A的疗效，并计划于2025年开始早期人体试验。","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":383298373657048,"gmtCreate":1734619989369,"gmtModify":1734619991526,"author":{"id":"3545282499782202","authorId":"3545282499782202","name":"多多吃苹果","avatar":"https://static.tigerbbs.com/432a70f360f69c451f37da889cb769b3","vip":1,"crmLevel":9,"crmLevelSwitch":0,"idStr":"3545282499782202","authorIdStr":"3545282499782202"},"htmlText":"一大片蓝海……","listText":"一大片蓝海……","text":"一大片蓝海……","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/383298373657048","repostId":1170079573,"repostType":4,"repost":{"id":"1170079573","kind":"news","weMediaInfo":{"introduction":"为用户提供金融资讯、行情、数据，旨在帮助投资者理解世界，做投资决策。","home_visible":1,"media_name":"老虎资讯综合","id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1734619328,"share":"https://www.laohu8.com/m/news/1170079573?lang=&edition=full","pubTime":"2024-12-19 22:42","market":"us","language":"zh","title":"Bio-Path开盘暴涨触发熔断，肥胖症实验性疗法取得积极结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1170079573","media":"老虎资讯综合","summary":"计划于2025年开始早期人体试验。","content":"<html><head></head><body><p>周四，药物开发商Bio-Path Holdings开盘暴涨触发熔断，现涨幅340.96%。消息面上，Bio-Path报告了一项临床前研究的积极结果，该研究测试其实验性疗法BP1001-A，以治疗2型糖尿病患者的肥胖症和相关代谢疾病。公司称，试验证实了BP1001-A在影响胰岛素信号传导方面的有效性。</p><p>公司已开始动物实验，以确认BP1001-A的疗效，并计划于2025年开始早期人体试验。</p><p></p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/1af69eaaf88a17b10941c28d63668c18\" tg-width=\"560\" tg-height=\"240\"/></p><p></p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bio-Path开盘暴涨触发熔断，肥胖症实验性疗法取得积极结果</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBio-Path开盘暴涨触发熔断，肥胖症实验性疗法取得积极结果\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/102\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">老虎资讯综合 </p>\n<p class=\"h-time\">2024-12-19 22:42</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>周四，药物开发商Bio-Path Holdings开盘暴涨触发熔断，现涨幅340.96%。消息面上，Bio-Path报告了一项临床前研究的积极结果，该研究测试其实验性疗法BP1001-A，以治疗2型糖尿病患者的肥胖症和相关代谢疾病。公司称，试验证实了BP1001-A在影响胰岛素信号传导方面的有效性。</p><p>公司已开始动物实验，以确认BP1001-A的疗效，并计划于2025年开始早期人体试验。</p><p></p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/1af69eaaf88a17b10941c28d63668c18\" tg-width=\"560\" tg-height=\"240\"/></p><p></p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/6ce1e2c9b06bd8104cffbddf43442c15","relate_stocks":{"BPTH":"Bio-Path Holdings, Inc."},"source_url":"","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1170079573","content_text":"周四，药物开发商Bio-Path Holdings开盘暴涨触发熔断，现涨幅340.96%。消息面上，Bio-Path报告了一项临床前研究的积极结果，该研究测试其实验性疗法BP1001-A，以治疗2型糖尿病患者的肥胖症和相关代谢疾病。公司称，试验证实了BP1001-A在影响胰岛素信号传导方面的有效性。公司已开始动物实验，以确认BP1001-A的疗效，并计划于2025年开始早期人体试验。","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":383356474884336,"gmtCreate":1734623149777,"gmtModify":1734624040565,"authorId":3583999381507169,"author":{"id":3583999381507169,"idStr":"3583999381507169","authorId":3583999381507169,"name":"军军2021","avatar":"https://static.tigerbbs.com/838e303518686eee475a4ae1b6ee739b","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":383298373657048,"type":1,"supId":0,"prevId":0,"content":"买的少赚了一点","text":"买的少赚了一点","html":"买的少赚了一点"}],"langContent":"CN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":3,"commentSize":2,"repostSize":1,"favoriteSize":6,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1170079573"}